Merck Reports P-III (KEYNOTE-689) Trial Data of Perioperative Keytruda for Locally Advanced Head and Neck Squamous Cell Carcinoma
Shots:
- The P-III (KEYNOTE-689) trial assessed neoadj. Keytruda (200mg, IV, Q3W × 2 cycles), followed by adj. Keytruda (× 15 cycles) + SoC radiotherapy (RT) ± cisplatin vs adj. SoC RT without cisplatin in treatment-naïve pts (n=714) with stage III/IVA resected LA-HNSCC; sBLA under the FDA’s review (PDUFA: Jun 23, 2025)
- At 38.3 mos. mFU, trial showed EFS risk reductions by 34% in CPS ≥10 pts (mEFS: 59.7 vs 26.9mos), 30% in CPS ≥1 pts (mEFS: 59.7 vs 29.6mos.), & 27% in ITT population (mEFS: 51.8 vs 30.4mos.)
- Trial showed improved mPR in ITT population & a 13.7% increase in pts with CPS ≥10; OS showed favorable trend but did not reach statistical significance at interim analysis & is under evaluation. Data to be presented at AACR 2025
Ref: Merck | Image: Merck
Related News:- Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
